October 31, 2022
PAR-22-250 - Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)
National Institute of General Medical Sciences (NIGMS)
All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.
Office of Data Science Strategy (ODSS)
The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the National Institutes of Health’s (NIH) interest in supporting data sciences research in Institutional Development Award (IDeA)-eligible states through PAR-22-250 “Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)”.
Research Objectives
The complexity and volume of basic, translational, and clinical research data continue to increase rapidly. To take full advantage of these data, it is critically important to foster innovative approaches to work with large research datasets and to develop a talented and diverse data science workforce. The NIH Office of Data Science Strategy (ODSS), which leads the implementation of the NIH Strategic Plan for Data Science through collaborations with NIH institutes, centers, and offices, intends to support one COBRE award to advance data science in IDeA states through this funding opportunity announcement, in addition to NIGMS' funding of meritorious COBRE Phase 1 applications that advance data science.
Applications aimed at building research capacity in a broad range of data science areas are welcome. These areas include artificial intelligence, clinical informatics, cloud computing, statistics, computational science, software design and programming, bioinformatics, visualization, machine learning, predictive analytics, supercomputing, modeling and simulation, data sharing and access, data management, data compression and standards, data security and data privacy in human subject’s research, and research ethics and integrity. Applications that propose to build capacity in multiple areas of data science, rather than a small number of narrowly focused areas, will be a priority for funding. The proposed center must address one or more of the five overarching goals of the NIH Strategic Plan for Data Science and adhere to the principles of making biomedical research data findable, accessible, interoperable, and reusable (FAIR).
ODSS does NOT award grants. Please contact the relevant NIH ICO program contact listed for questions related to NIH ICO research priorities and funding.
Application and Submission Information
This NOSI applies to the January 30, 2023, January 30, 2024, and January 30, 2025 due dates.
Applications for this NOSI must be submitted to and be in full compliance with the following Funding Opportunity Announcement (FOA):
- PAR-22-250 - Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional).
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
- For funding consideration, applicants must include “NOT-GM-23-011” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Federico Bernal, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]
Raphael Isokpehi, Ph.D.
NIH Office of Data Science Strategy (ODSS)
Email: [email protected]
and Human Services (HHS)
